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Objectives: There are controversial studies investigating whether multiple anti-Mullerian
hormone (AMH) measurements can improve the individualized prediction of age at
menopause in the general population. This study aimed to reexplore the additive role of
the AMH decline rate in single AMH measurement for improving the prediction of age at
physiological menopause, based on two common statistical models for analysis of time-
to-event data, including time-dependent Cox regression and Cox proportional-hazards
regression models.
Methods: A total of 901 eligible women, aged 18–50 years, were recruited from the
Tehran Lipid and Glucose Study (TLGS) population and followed up every 3 years for 18
years. The serum AMH level was measured at the time of recruitment and twice after
recruitment within 6-year intervals using the Gen II AMH assay. The added value of
repeated AMHmeasurements for the prediction of age at menopause was explored using
two different statistical approaches. In the first approach, a time-dependent Cox model
was plotted, with all three AMH measurements as time-varying predictors and the
baseline age and logarithm of annual AMH decline as time-invariant predictors. In the
second approach, a Cox proportional-hazards model was fitted to the baseline data, and
improvement of the complex model, which included repeated AMH measurements and
the logarithm of the AMH annual decline rate, was assessed using the C-statistic.
Results: The time-dependent Cox model showed that each unit increase in the AMH level
could reduce the risk of menopause by 87%. The Cox proportional-hazards model also
improved the prediction of age at menopause by 3%, according to the C-statistic. The
subgroup analysis for the prediction of early menopause revealed that the risk of early
menopause increased by 10.8 with each unit increase in the AMH annual decline rate.
Conclusion: This study confirmed that multiple AMH measurements could improve the
individual predictions of the risk of at physiological menopause compared to single AMHn.org September 2021 | Volume 12 | Article 7272291
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Frontiers in Endocrinology | www.frontiersimeasurements. Different alternative statistical approaches can also offer the same
interpretations if the essential assumptions are met.Keywords: anti-Mullerian hormone, menopause, proportional hazard Cox regression, Tehran Lipid and Glucose
Study, time-dependent Cox regressionINTRODUCTION
Menopause is a unique event in a woman’s life, with significant
physical, psychological, and social effects on her health (1). In
this phenomenon, the main biological change is a reduction of
the primordial follicle pool, leading to menopause at the mean
age of 51 years (2). Overall, the accurate estimation of age at
menopause can enable women to make informed decisions about
their future fertility and desired family size. Also, strategies can
be devised for reducing the short- or long-term health risks of
early and late menopause.
So far, many candidate markers have been identified to
estimate the age at menopause. Considering the strong
association between women’s age, number of primordial and
growing follicles, and serum anti-Mullerian hormone (AMH)
levels, efforts have been made for the individualized prediction of
age at menopause, based on the serum concentrations of AMH.
Generally, this hormone is a member of the transforming growth
factor-b (TGF-b) family, which is produced by follicular
granulosa cells of small growing follicles.
So far, several studies have been performed to examine the
association between age at menopause and the serum
concentration of AMH using various mathematical models (3–
8). However, the serum AMH level appears to have limited
precision at an individual level, particularly for women with an
early menopause. Besides, there is uncertainty regarding the
added value of repeated AMH measurements for improving
the prediction of age at menopause. It is well documented that
the ovarian reserve status is not constant throughout one’s life
and is influenced by different intrinsic and extrinsic factors (9–
14); therefore, it is hypothesized that serial AMH measurements
may indirectly estimate these changes.
Controversial results have been reported in studies
investigating whether multiple AMH measurements can
improve the individualized prediction of age at menopause in
the general population (15–19). Apart from different complex
and dynamic factors, such as ethnicity, age range, duration of
follow-up, and study design that can cause discrepancy between
studies, the statistical models used for the analysis of data may be
also influential. Although Cox models have been widely used for
data analysis, the absence of essential assumptions and technical
intricacies may lead to bias in estimations of regression
coefficients in these models.
In our previous study (19), we reported that prediction of age
at menopause could be improved by multiple AMH
measurements, using an accelerated failure time model with
the Weibull distribution, while another well-designed study
reported no added value for repeated AMH measurements
based on the Cox proportional-hazards models with time-
varying covariates (16). Therefore, in the present study,n.org 2we aimed to reanalyze our dataset using the most common
Cox regression models, based on the essential assumptions to
reexplore the added value of AMH decline rate to single
AMH measurements for improving the prediction of age at
physiological menopause.MATERIALS AND METHODS
This study was approved by the ethics committee of the Research
Institute for Endocrine Sciences, and a written informed consent
was obtained from all subjects before initiation of the study (No.
IR.SBMU.ENDOCRINE.REC.1395.347).
Study Participants
The participants of this study were selected from the population
of Tehran Lipid and Glucose Study (TLGS), which is an ongoing,
long-term, population-based prospective study, initiated in 1998
to evaluate the risk factors for non-communicable disorders in
an urban population. A more exhaustive description of the TLGS
is published elsewhere (20).
The present study was performed on all female TLGS
participants, aged 18–50 years, with regular and predictable
menstrual cycles and proven natural fertility at the beginning
of the study. The exclusion criteria were as follows: being
currently pregnant; a history of hysterectomy, oophorectomy,
or any type of ovarian surgery; premature menopause before the
age of 40 years; all those women age < 40 at the end of study;
current use of psychotropic or hormonal medications, including
hormonal contraceptives or hormone therapies; and serious
diseases known to interfere with the ovarian function, such as
breast or endometrial cancer and endocrine disorders.
Study Design
The cohort was followed up for 18 years after enrollment in the
study (1998–2001). They completed a standard questionnaire
(including the reproductive history and date of the last menstrual
cycle) in face-to-face interviews with trained staff once at baseline
and every 3 years after enrollment in the study in the follow-up
visits. Besides, a general practitioner performed the general
anthropometric measurements and physical examinations.
After 12–14 h overnight fasting, blood samples were obtained
from the subjects between 07:00 a.m. and 09:00 a.m., the plasma
was separated in a refrigerated centrifuge at 3,000 rpm for
10 min, and the sera were stored at -80°C for further assessments.
Study Variables
According to the World Health Organization (WHO)
classification, natural menopause occurs after 12 consecutive
months of amenorrhea, for which there is no other obviousSeptember 2021 | Volume 12 | Article 727229
Ramezani Tehrani et al. AMH and Age at Menopausepathological or physiological cause (21). The date of menopause
was defined as a point in time 12 months after a woman’s
last period.
The AMH level was measured at three time points (baseline,
third and sixth follow-up), using a two-site enzyme
immunoassay with Gen II Kit (Beckman Coulter, Inc.,
Fullerton, CA, USA) and a Sunrise ELISA reader (Tecan Co.,
Salzburg, Austria). A modified protocol was used for measuring
the AMH levels, as the original Gen Kit may underestimate the
serum AMH level (22). A single experienced laboratory
technician performed all AMH measurements simultaneously
at the same laboratory. The AMH Gen II control A79766 was
used at two concentrations to monitor the accuracy of assays.
The intra- and inter-assay coefficients of variation were
estimated at 1.9% and 2.0%, respectively.
Statistical Method
For elimination of outlier effects, we used 95% trim data. Initially,
we defined three age categories: 18–30, 31–40, and 41–50 years.
For all these categories, the 2.5th and 97.5th percentiles of AMH
values were calculated, and any observation beyond these values
was removed. Moreover, for a survival analysis, we considered
the observation time to be the most recent information about the
age of women who did not experience menopause or the
menopausal age of women who reached menopause during
the study. Besides, the storage time for AMH was determined
as the time interval between sample collection and AMH
measurements. The AMH annual decline rate was also
calculated based on the difference between the first and the last
measured AMH, divided by the interval between these
two measurements.
To assess the added value of a second AMHmeasurement, we
employed a stepwise approach. First, the baseline AMH level was
considered as the predictor of age at menopause in a Cox
proportional-hazards model. In the next model, the second
AMH measurement was integrated. In Model 3, the logarithm
of the annual AMH decline rate was included instead of the
second AMH measurement. Finally, Model 4 included both the
second AMH measurement and logarithm of annual AMH
decline. All these models were adjusted by age at baseline and
AMH storage time of the samples. Nevertheless, a third AMH
measurement was not considered in the analysis due to lack of
follow-up after this point.
The predictive power of the models was evaluated by the C-
statistic. Moreover, the proportional hazards (PH) assumption
for the Cox regression models was examined, using the cox.zph
function in the survival package of R software (15). This function
examines the proportionality of all predictors included in the
model by creating interactions with time. A small p-value can
indicate a violation of the PH assumption. Besides, we generated
a plot for each AMH measurement and logarithm of annual
AMH decline rate in the models. If the PH assumption is met, a
slope of zero is inevitable in the plot. On the other hand, a slope
that significantly diverges from zero suggests a violation of the
PH assumption (15).
Generally, correlations between predictors, including
different AMH measurements and the AMH annual declineFrontiers in Endocrinology | www.frontiersin.org 3rate, may cause multicollinearity issues. Therefore, we used the
variance inflation factor (VIF) index to quantify the level of
multicollinearity. A VIF of 1 suggests that there is no correlation
between the predictor of interest and the remaining predictive
variables; therefore, variance in this predictor is not inflated at
all. As a general rule, VIFs exceeding 4 require further
investigation, while VIFs exceeding 10 suggest serious
multicollinearity requiring a model correction (23).
As an alternative approach, we used the time-dependent Cox
model to evaluate the predictive power of all AMH
measurements for age at menopause. Overall, when the PH
assumption is violated, it is suggested to use extended Cox
models, such as time-dependent Cox models. We considered
two scenarios for modeling the relationship between the AMH
level and age at menopause. In the first approach, we used the
time-dependent Cox model to evaluate the predictive power of
all three AMH measurements for age at menopause. The
logarithm transformation of these values was included in the
model, and the observation time and AMH annual decline rate
were defined as described earlier. The AMH levels and AMH
storage time were also entered in the models as time-varying
predictors, while the baseline age and logarithm of annual AMH
decline rate were considered as time-invariant variables.
To explore the value of repeated AMH measurements for the
prediction of early menopause (menopause <45 years), a
subgroup analysis was performed, including an observation
time <45 years. Statistical analyses were performed in R
Version 4.0.2 (R Foundation for Statistical Computing, Vienna,
Austria) (24).RESULTS
A total of 901 TLGS participants met the eligibility criteria and
were observed for a median follow-up of 13 years (interquartile
range [IQR]: 9–16); overall, 522 women reached menopause
during the study. The mean (SD) age of the subjects was 36 (6.0),
43 (5.9), and 50 (5.2) years at baseline and in the third and sixth
follow-ups, respectively, and the mean body mass index (BMI)
was 27 (4.7), 28 (4.4), and 29 (4.8) kg/m2, respectively (Table 1).
Moreover, the mean (SD) serum AMH levels were 1.5 (1.5),
0.66 (0.75), and 0.32 (0.44) ng/ml at baseline and in the third and
sixth follow-ups, respectively. Also, the mean age-specific AMH
annual decline rates for the 5th, 25th, 50th, 75th, and 95th
percentiles of our population were estimated at 0.006, 0.032,
0.079, 0.14, and 0.29 ng/ml, respectively. Figure 1 compares our
method for identification of outliers (trimming the dataset) with
graphic box plots as the most common method. It was found that
eliminated data in our approach (presented as red dots) were
much less than the common approach.
Table 2 compares the C-statistics for the Cox proportional-
hazards model, including single baseline AMH measurements,
and advanced models, including repeated AMH measurements
and logarithm of annual AMH decline rate (Table 2). In Model 1
with the baseline AMH values, the risk of experiencing
menopause during the follow-ups decreased by 57% with each
unit (ng/mL) increase in the baseline serum AMH levels inSeptember 2021 | Volume 12 | Article 727229
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at second time points decreased the C-statistic to 0.70 in Model 2,
and adding the AMH annual decline rate to Model 1 improved
the C-statistic by 3% (0.74). In other words, with each unitFrontiers in Endocrinology | www.frontiersin.org 4increase in logarithm of annual AMH decline rate (ng/mL/y), the
risk of menopause increased by 37%.
For further clarification, assume that we want to evaluate the
time to menopause in two females with similar age. The mean
baseline level of AMH was 1.8 ng/ml in these two cases. The
second measurement showed that the AMH level of subject
1 reduced to 1.7 ng/ml after 1 year, while the AMH level reduced
to 1.53 ng/ml in subject 2. Overall, the risk of earlier menopause
in subject 2 was 37% higher than in subject 1; interestingly, the
risk of early menopause was 2.33 times higher in subject 2.
However, this key finding would have been missed if we had not
conducted the second measurements.
Both the second AMH measurements and the logarithm of
annual AMH decline rate decreased the C-statistic to 0.73 in
Model 4. However, according to the C-statistic, the best model
for predicting menopause/early menopause was Model 3. Based
on the PH assumption, none of the models could satisfy all of the
included variables considering the p-values < 0.05, except for the
baseline AMH measurement in Model 2 (p = 0.175); however,
the assumptions of the second AMH measurement and the
global model were violated (p < 0.05).
Figure 2 is a visual representation of the PH assumption in our
models. Although the results showed that the PH assumption
held true for the baseline AMH values in Models 2, 3, and 4, the
related lines suggest deviations from this assumption. However,
this test only considered linear time trends, while a higher order of





N = 901 N = 859 N = 638
Age (year), mean (SD) 36 (6.0) 43 (5.9) 50 (5.2)
<30 (year), n (%) 172 (19.09) 131 (15.25) -
31–40 (year), n (%) 447 (49.61) 290 (33.76) -
>40 (year), n (%) 282 (31.30) 438 (50.99) 638 (100)
BMI (kg/m2) 27 (4.7) 28 (4.4) 29 (4.8)
<25 (kg/m2), n (%) 290 (32.19) 280 (32.60) 123 (19.28)
25–29 (kg/m2), n (%) 373 (41.40) 355 (41.33) 233 (36.52)
≥30 (kg/m2), n (%) 230 (25.53) 216 (25.15) 171 (26.80)
WC (cm), mean (SD) 85 (11) 88 (12) 85 (11)
WHR, mean (SD) 0.82 (0.07) 0.82 (0.07) 0.82 (0.06)
Parity, n (%) 2.5 (1.5) 2.5 (1.5) 2.0 (1.5)
Central obesity *, n (%) 377 (42.6) 356 (42.23) 386 (61.86)
AMH **, (ng/ml) 1.5 (1.5) 0.66 (0.75) 0.32 (0.44)
Storage time for AMH, ** (year) 8.7 (0.5) 4.2 (0.9) 1 (0.8)
Menopause, N (%) 0 (0) 194 (22) 522 (82)Values are given as mean (standard deviation), or number (percentage), as indicated.
BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; AMH, anti-
Mullerian hormone.
*Central obesity is defined as a waist circumference ≥ 88 cm.
**Only reported for those not reached menopause.September 2021 | Volume 12 | Article 727229
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4 in the first three models; in other words, there was no significant
collinearity requiring further exploration. However, the VIF for
Model 4 was about 10 (9.89), which revealed a severe
multicollinearity requiring model correction.
The results of the subgroup analysis for the prediction of early
menopause are presented in Table 2. It was found that the AMH
annual decline rate was the most effective predictor. Each unit
increase in the logarithm of decline rate multiplied the risk of
menopause by 2.38. Equivalently, the risk of early menopause
increased by 10.8 with each unit increase in the AMH annual
decline rate. Based on the C-statistic, the best model for
predicting early menopause included the baseline AMH
measurement and the AMH annual decline rate (C-statistic =
0.75); the hazard ratios for the baseline AMH and the annual
AMH decline rate were 0.22 and 2.33 in this model, respectively.
However, only Model 2, which included both the baseline
and second AMH measurements, satisfied the PH assumption
(p = 0.75). The VIF did not exceed the cutoff value of four in the
first three models, while it was 12.91 in Model 4; therefore,
inclusion of both AMH measurements and the logarithm of the
decline rate in Model 4 caused considerable multicollinearity.
Table 3 summarizes the results of our second approach, based
on the time-dependent Cox regression analysis. Model 1
considered the AMH measurement at each time point as the
primary predictor and was adjusted for the baseline age.
According to this model, the risk of menopause decreased by
87% with each unit increase in the AMH value (ng/mL). Besides,
the addition of AMH storage time to the model increased theFrontiers in Endocrinology | www.frontiersin.org 5C-statistic by 21%. Model 3 incorporated the logarithm of the
annual AMH decline rate instead of rather than the AMH values;
although the C-statistic was 84%, the hazard ratio was
not significant.
Finally, Model 4 included both AMH measurements and
AMH annual decline rate; the hazard ratio for AMH was the
same as Model 2, and the decline rate was still insignificant.
Therefore, in the presence of AMH levels at each observation
time, the decline rate did not add any information. Also, the
subgroup analysis for the prediction of early menopause revealed
similar results (Table 3). Moreover, in a comparison of two
subjects with the same conditions and a 1-ng/ml difference in the
AMH level, Model 2 indicated a 90% lower risk of early
menopause. Under different conditions, Model 3 provided
information about time variations in the AMH levels.
Therefore, the risk of early menopause in women with a one-
unit decline rate was 3.52 times higher than that of women with a
stable AMH over a year.DISCUSSION
The present study revealed that regardless of using various
statistical approaches, repeated AMH measurements could
improve the prediction of age at menopause or early
menopause. It should be emphasized that models including
both AMH level in each observation time and the annual
decline rate of AMH cause multicollinearity issues, as they
obscure the beneficial effects of multiple AMH measurementsTABLE 2 | Summary of statistics for the proportional hazard Cox regression approach (include test of proportional hazards assumption) for prediction of menopause/
early menopause according to single/repeated AMH measurements.
Variable Menopause prediction during follow-up Prediction of early menopause€








Model 1* 0.71 (0.69–0.73) 0.71 (0.69–0.73)
Global PH assumption 0.002 0.011
Baseline AMH value 0.43 (0.37–0.50) 0.013 1.40 0.44 (0.38–0.52) 0.003 1.27
Model 2** 0.70 (0.68–0.72) 0.73 (0.69–0.78)
Global PH assumption 0.006 0.75
Baseline AMH 0.49 (0.39–0.61) 0.173 3.03 0.49 (0.33–0.72) 0.70 2.75
Second AMH value 0.78 (0.49–1.25) 0.011 2.88 0.71 (0.35–1.45) 0.23 2.83
Model 3** 0.74 (0.71–0.76) 0.75 (0.71–0.79)
Global PH assumption <0.001 0.028
Baseline AMH value 0.29 (0.23–0.37) 0.177 2.60 0.22 (0.14–0.34) 0.440 2.58
Log (annual AMH decline
rate£)
1.37 (1.20–1.56) 0.056 1.92 2.33 (1.49–3.63) 0.101 2.61
Model 4** 0.73 (0.70–0.75) 0.75 (0.71–0.80)
Global PH assumption <0.001 0.197
Baseline AMH value 0.19 (0.12–0.30) 0.122 9.90 0.06 (0.02–0.16) 0.341 12.91
Second AMH value 2.34 (1.22–4.49) 0.004 5.55 5.95 (1.74–20.36) 0.094 7.63
Log (annual AMH decline
rate)
1.56 (1.31–1.86) 0.044 3.11 4.34 (2.35–8.02) 0.255 4.17September 2021 | Volume 12*Model 1: adjusted by age at baseline and storage time of baseline AMH.
**Models 2, 3, and 4: adjusted by age at baseline, storage times of baseline, and second AMH measures.
Significant results are reported in bold.
AMH, anti-Mullerian hormone; HR, hazard ratio; VIF, variation inflation factor; PH, proportional hazard.
£Annual AMH decline rate was calculated according (last AMH-baseline AMH)/time intervals (years), reported as AMH (ng/ml/year).
€Early menopause was defined as menopause occurred at age 40–45 years.| Article 727229
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Cox proportional-hazards and time-dependent regression
models, the former was found to be less suitable, since the PH
assumption was not satisfied for repeated measurements of
AMH, while the time-dependent Cox regression model did notFrontiers in Endocrinology | www.frontiersin.org 6meet this assumption, and multicollinearity may not influence
the results.
Previous studies have shown that a single AMHmeasurement
cannot be a sensitive indicator for the prediction of age at
menopause at an individual level (24–26). The majority ofTABLE 3 | Summary statistics for the time-dependent Cox regression approach for prediction of menopause/early menopause according to single/repeated AMH measurements.
Variable Menopause prediction during follow-up Prediction of early menopause€
HR (95% CI) C-statistic (95% CI) HR (95% CI) C-statistic (95% CI)
Model 1* 0.71 (0.61–0.96)
AMH value 0.13 (0.04–0.48) 0.64 (0.61–0.67) 0.07 (0.00–6.45)
Model 2** 0.74 (0.64–0.95)
AMH value 0.03 (0.003–0.22) 0.85 (0.83–0.87) 0.09 (0.001–6.51)
Model 3** 0.83 (0.75–0.91)
Log (annual AMH decline rate) 0.92 (0.84–1.01) 0.84 (0.83–0.85) 2.35 (1.02–5.40)
Model 4** 0.72 (0.59–0.96)
AMH value 0.03 (0.003–0.23) 0.02 (0.00–11.60)
Log (annual AMH decline rate) 1.00 (0.91–1.10) 0.85 (0.83–0.87) 2.77 (0.96–8.02)September 2021 | Volum*Model 1: adjusted by age at baseline.
**Models 2, 3, and 4: adjusted by age at baseline and storage time of AMH.
Significant results are reported in bold. Annual AMH decline rate was calculated according to last AMH-baseline AMH)/time intervals (years), reported as AMH (ng/ml/year).
AMH, anti-Mullerian hormone; HR, hazard ratio.
€Early menopause was defined as menopause that happened at age < 45 years.FIGURE 2 | The visual assessment of proportional hazard assumption for Cox regression models. Model 1: The effect of baseline AMH measurement on survival
time adjusted by age at baseline and storage time for baseline AMH. Model 2: The effects of baseline and second AMH measurements on survival time adjusted by
age at baseline, storage times of baseline, and second AMH measure. Model 3: The effects of baseline AMH measurement and logarithm of AMH annual decline rate
on survival time adjusted by age at baseline, storage times of baseline, and second AMH measure. Model 4: The effects of baseline AMH measurement, second
AMH measurement, and logarithm of AMH annual decline rate on survival time adjusted by age at baseline, storage times of baseline, and second AMH measure.e 12 | Article 727229
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resulting in a comparable decreasing pattern for each woman
(17, 27). Although the level of AMH is primarily determined by
the initial primordial follicle pool size (27), its level may be
influenced by biological characteristics, reproductive factors, or
environmental/lifestyle factors (9–14, 28), leading to a complex
pattern of AMH decline.
Freeman et al., in the 14-year population-based Penn Ovarian
Aging Stud, found that adding the change rate of AMH to the single
AMH measurement or age alone could improve the estimation of
time to menopause (17). Besides, de Kat et al., in the 20-year
population-based Doetinchem Prospective Study, reported that the
decline in age-dependent AMH levels did not follow a fixed pattern
for each woman, as it varied significantly for individuals over time
(15). It was hypothesized that adding the AMH change rate to a
prediction model with a single AMH measurement might improve
the prediction of age at menopause. However, studies using
repeated AMH measurements have reported conflicting results,
mainly due to the use of different statistical approaches and not
meeting the essential preliminary assumptions.
Moreover, in a smaller subset of the TLGS population,
including 266 women with a shorter average follow-up of 6.5
years, we found that multiple AMHmeasurements could provide
an individualized prediction of age at menopause (18). However,
with a larger sample size, a higher menopausal event rate, a
longer follow-up of TLGS study (19), and also use of an
accelerated failure time model with the Weibull distribution,
we found that prediction of age at menopause could be improved
if the annual decline rate was added to the model including AMH
alone; the C-statistic increased from 70% to 78%, and the
difference between the actual and predicted age at menopause
decreased from -0.48 to -0.21 years (19).
In contrast, in another recent study, de Kat et al. reanalyzed
the data of 2,434 premenopausal women from the population-
based Doetinchem Cohort Study. Based on the time-varying Cox
model, the AMH decline rate alone or in combination with age-
specific AMH had a small added value; they concluded that
knowledge of the AMH decline rate does not improve the
prediction of menopause (16). Although this discrepancy may
be partially explained by the heterogeneity of population
characteristics and use of different statistical approaches, in the
present study, we aimed to reexamine our dataset using time-
varying Cox modeling to explore the factors that may partly
explain these controversial findings.
The Cox proportional-hazards regression modeling is
commonly used to analyze the survival data. However, the
critical assumption of this model has been rarely examined in
applied studies (4, 7, 29). According to the PH assumption, the
hazard ratio should be constant over time; in other words, the
hazard for one individual is proportional to the hazard for any
other individual. Besides, the proportionality constant is
independent of time (30). As the estimation technique in Cox
regression models depends on the PH assumption, a violationmay
lead to an incorrect inference or underestimation of the hazard
ratio (in case of an increase in the hazard proportion) (31, 32).
In the present study, we explored the adequacy of Cox
models, using time-weighted score tests of the proportional-Frontiers in Endocrinology | www.frontiersin.org 7hazards hypothesis (33). The results revealed that the PH
assumption was violated if we considered only one value for all
AMH measurements, as reported by de Kat et al. (16). In other
words, the hazard ratio varies with time and depends on the
magnitude of change. Therefore, parametric models, extended
Cox regression for time-varying variables, and joint modeling
have been suggested (19, 29, 31, 34). The time-dependent Cox
regression model has been extended for when a variable cannot
satisfy the PH assumption. This model is more appropriate for
covariates that vary as a function of time (external covariates)
(35). Time dependence is considered in the model by entering
different values of covariates and clustering them for the
individual. Therefore, the model easily handles variations in
covariates across time (36).
On the other hand, the multicollinearity of dependent
variables in all regressions can cause serious problems, such as
undermining the statistical significance of variables (37). In the
study by de Kat et al., while a time-dependent Cox regression
model was used with an appropriate C-statistic (0.70), adding the
AMH annual decline rate did not improve the C-statistic, and
the hazard ratio of this rate changed the effects (from 1.36 in the
crude model to 0.98 in the adjusted model by AMH levels) (16).
This discrepancy may be partly explained by the inclusion of
both AMH values and their variations in the time-dependent
Cox model, because it led to multicollinearity which did not
improve the predictions.
The main strength of the present study was its methodology,
as it was a large population-based research with long-term
follow-ups using advanced statistical methods while meeting
the essential assumptions. Menopause occurred in more than
half of the participants during the follow-ups, which improved
the reliability of our predictions. Moreover, the intra- and inter-
assay variability in AMH measurements was minimal due to the
use of a single AMH kit and performing all measurements in a
single laboratory.
This study also had some limitations. First, other ovarian
aging markers, such as the antral follicle count, were not
measured. Second, we used the Gen II assay (Beckman
Coulter, CA, USA) for the AMH measurements. Compared to
the picoAMH assay (Ansh Labs LLC, TX, USA), the Gen II assay
has less sensitivity, particularly in the lower range of AMH,
resulting in a higher limit of detection (38); however, there seems
to be a significant correlation between these two assays (39).
Third, use of stored frozen samples for AMHmeasurements may
potentially affect the stability of AMH. However, it has been
documented that storage at -80°C and episodes of thawing have
little effects on the AMH level, according to the AMH Gen II
assay (40, 41). Fourth, our results remained unchanged after
adjustment for the sample storage time as the confounding
variable. However, it remains unclear whether the current
findings obtained from women with a previously normal
fertility can be translated to infertile women in whom the
ovarian aging process may be compromised. Overall, 9.4% of
our population were younger than 40 years, and one-third of
them did not reach menopause; however, the occurrence of
menopause was adequate for achieving reliable results in
this study.September 2021 | Volume 12 | Article 727229
Ramezani Tehrani et al. AMH and Age at MenopauseIn conclusion, this study confirmed that multiple AMH
measurements can improve the individualized prediction of
physiological menopause age compared to single AMH
measurements. Also, different alternative statistical approaches
can offer the same interpretations of findings if the essential
assumptions are met. However, use of multiple AMH
measurements for the prediction of age at menopause in
clinical practice still requires further investigation.DATA AVAILABILITY STATEMENT
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